{
    "info": {
        "nct_id": "NCT03396874",
        "official_title": "Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence",
        "inclusion_criteria": "1. Histopathological proven prostate adenocarcinoma.\n2. Rising prostate specific antigen (PSA) after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy).\n\n   1. Post radical prostatectomy (RP) - according to American Urological Association (AUA) recommendation criteria: PSA greater than 0.2 ng/mL measured more than 6 weeks after RP and confirmatory persistent PSA greater than 0.2 ng/mL.\n   2. Post-radiation therapy - according to ASTRO-Phoenix consensus definition: Nadir + greater than or equal to 2 ng/mL rise in PSA.\n3. Karnofsky performance status of ≥ 50.\n4. Age ≥ 18.\n5. Ability to understand a written informed consent document, and the willingness to sign it.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Current investigational therapy for prostate cancer.\n2. Unable to lie flat, still or tolerate a PET/CT scan.\n3. Prior history of a malignancy within the last 2 years, except skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized, and except superficial bladder cancer.\n4. Prisoner.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Must be MALE",
            "criterions": [
                {
                    "exact_snippets": "Must be MALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Rising prostate specific antigen (PSA) after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy).",
            "criterions": [
                {
                    "exact_snippets": "Rising prostate specific antigen (PSA)",
                    "criterion": "prostate specific antigen (PSA)",
                    "requirements": [
                        {
                            "requirement_type": "trend",
                            "expected_value": "rising"
                        }
                    ]
                },
                {
                    "exact_snippets": "after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy)",
                    "criterion": "prior definitive therapy for prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "treatment_history",
                            "expected_value": [
                                "prostatectomy",
                                "radiation therapy (external beam or brachytherapy)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Post radical prostatectomy (RP) - according to American Urological Association (AUA) recommendation criteria: PSA greater than 0.2 ng/mL measured more than 6 weeks after RP and confirmatory persistent PSA greater than 0.2 ng/mL.",
            "criterions": [
                {
                    "exact_snippets": "Post radical prostatectomy (RP)",
                    "criterion": "radical prostatectomy",
                    "requirements": [
                        {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "PSA greater than 0.2 ng/mL measured more than 6 weeks after RP",
                    "criterion": "prostate-specific antigen (PSA) level after RP",
                    "requirements": [
                        {
                            "requirement_type": "time since RP",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "PSA level",
                            "expected_value": {
                                "operator": ">",
                                "value": 0.2,
                                "unit": "ng/mL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "confirmatory persistent PSA greater than 0.2 ng/mL",
                    "criterion": "confirmatory persistent PSA level",
                    "requirements": [
                        {
                            "requirement_type": "PSA level",
                            "expected_value": {
                                "operator": ">",
                                "value": 0.2,
                                "unit": "ng/mL"
                            }
                        },
                        {
                            "requirement_type": "persistence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Post-radiation therapy - according to ASTRO-Phoenix consensus definition: Nadir + greater than or equal to 2 ng/mL rise in PSA.",
            "criterions": [
                {
                    "exact_snippets": "Post-radiation therapy",
                    "criterion": "prior radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "according to ASTRO-Phoenix consensus definition: Nadir + greater than or equal to 2 ng/mL rise in PSA",
                    "criterion": "PSA rise after nadir",
                    "requirements": [
                        {
                            "requirement_type": "increase from nadir",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "ng/mL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Ability to understand a written informed consent document, and the willingness to sign it.",
            "criterions": [
                {
                    "exact_snippets": "Ability to understand a written informed consent document",
                    "criterion": "ability to understand written informed consent document",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willingness to sign it",
                    "criterion": "willingness to sign informed consent document",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Age ≥ 18.",
            "criterions": [
                {
                    "exact_snippets": "Age ≥ 18",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Karnofsky performance status of ≥ 50.",
            "criterions": [
                {
                    "exact_snippets": "Karnofsky performance status of ≥ 50",
                    "criterion": "Karnofsky performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": ""
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Histopathological proven prostate adenocarcinoma.",
            "criterions": [
                {
                    "exact_snippets": "Histopathological proven prostate adenocarcinoma",
                    "criterion": "prostate adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "confirmation_method",
                            "expected_value": "histopathological"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "4. Prisoner.",
            "criterions": [
                {
                    "exact_snippets": "Prisoner.",
                    "criterion": "prisoner status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Current investigational therapy for prostate cancer.",
            "criterions": [
                {
                    "exact_snippets": "Current investigational therapy for prostate cancer",
                    "criterion": "investigational therapy for prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Unable to lie flat, still or tolerate a PET/CT scan.",
            "criterions": [
                {
                    "exact_snippets": "Unable to lie flat",
                    "criterion": "ability to lie flat",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Unable to ... still",
                    "criterion": "ability to remain still",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Unable to ... tolerate a PET/CT scan",
                    "criterion": "ability to tolerate a PET/CT scan",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Prior history of a malignancy within the last 2 years, except skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized, and except superficial bladder cancer.",
            "criterions": [
                {
                    "exact_snippets": "Prior history of a malignancy within the last 2 years",
                    "criterion": "prior malignancy",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized",
                    "criterion": "skin basal cell carcinoma or cutaneous superficial squamous cell carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "metastasis",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "except superficial bladder cancer",
                    "criterion": "superficial bladder cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}